Handelsavisen
prelaunch
Companies ›Healthcare ›8432.TWO
84
8432.TWO — TPEx Pharmaceuticals

TSH Biopharm Corp Ltd

$49,25
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
4,23 %
Op margin
16,3 %
ROE
9,7 %
Net margin
10,4 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

TSH Biopharm Corp Ltd is a pharmaceutical company that develops and commercializes biopharmaceutical products, primarily in the oncology and autoimmune disease treatment segments.

Business. TSH Biopharm Corp Ltd (8432.TWO) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm is listed on the Taiwan Premium Exchange (TPEx) under the ticker 8432.TWO. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a product-sale entity within the pharmaceuticals industry.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target—

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
—
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
1 analysts · indicative
Ownership
—
not yet wired
Profitability→
9,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 8432.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 8432.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TSH Biopharm Corp Ltd (8432.TWO) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm is listed on the Taiwan Premium Exchange (TPEx) under the ticker 8432.TWO. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a product-sale entity within the pharmaceuticals industry.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    TSH Biopharm Corp Ltd maintains a strong liquidity position, with a current ratio of 6.27 and cash and equivalents amounting to 464.54 million TWD. The company's low debt-to-equity ratio of 0.01 indicates a conservative capital structure, with minimal long-term debt exposure. This liquidity profile supports operational flexibility and reduces financial risk.

    Profitability metrics show a return on equity (ROE) of 9.65% and a return on assets (ROA) of 7.14%, both of which are strong indicators of efficient capital use and asset management. The company's net income of 139.26 million TWD and operating income of 218.37 million TWD reflect solid earnings performance. These figures are in line with industry expectations for a mid-sized pharmaceutical firm.

    The company's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic diversification. This concentration may expose the company to regional market risks, particularly in the event of regulatory changes or economic downturns in its primary operating region.

    Looking ahead, TSH Biopharm Corp Ltd is projected to grow revenue to 1.46 billion TWD in the current fiscal year, representing a modest increase from the current 1.34 billion TWD. Analysts expect the company to maintain its earnings momentum, with a mean EPS estimate of 4.03 TWD. The company's capital expenditure of -10.4 million TWD suggests a focus on cost optimization rather than expansion.

    The company's risk profile is characterized by low liquidity and dilution risks. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal, indicating no near-term dilution pressure.

    Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial health. The company's financial performance and risk profile remain consistent with its historical trends, and there are no signs of distress or strategic shifts in the near term.

    Key takeaways
    • TSH Biopharm Corp Ltd maintains a strong liquidity position with a current ratio of 6.27 and minimal debt exposure.
    • The company's profitability metrics, including ROE of 9.65% and ROA of 7.14%, indicate efficient capital use and asset management.
    • Revenue is concentrated in the core pharmaceutical business, with no disclosed geographic diversification.
    • Analysts project modest revenue growth to 1.46 billion TWD, with a mean EPS estimate of 4.03 TWD.
    • The company's risk profile is low, with no immediate liquidity or dilution flags detected.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $49,25
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $1.44B
    Net cashⓘ
    $445.9M
    Current ratioⓘ
    6.3
    Debt / equityⓘ
    0.0
    ROAⓘ
    7.1%
    ROEⓘ
    9.7%
    Cash conversionⓘ
    100.0%
    CapEx / revenueⓘ
    -0.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    Operating income · consensus254,0M TWD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin16,3 %Above P75
    Net Margin10,4 %Above median
    ROE9,7 %Above median
    Capex / Rev-0,8 %Above P75
    D/E0,01Above median
    Cash Conv1,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TSH Biopharm Corp Ltd Market data — financials · 2026-05-27
    • TSH Biopharm Corp Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    8432.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage